Clinical Trials Arena on MSN10d
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
Nature5y
Akt takes centre stage in cell-cycle deregulation
The universal cell-cycle inhibitor p21 Cip1/WAF1 is phosphorylated and localized in the cytoplasm in Her2/neu-overexpressing breast cancers as a result of its physical association with the ...